![]() |
||||
![]() |
||||
![]() |
||||
|
Disclaimer • Welcome • Why Alternatives? • Alternative Cancer Therapy Guides |
||||
|
||||
![]() |
The angiogenesis cascade of endothelial cell activation, degradation of the extracellular matrix and the basal membrane, migration and proliferation. EC, endothelial cell; BM, basal membrane; AS, angiogenic stimulus (reviewed in Griffioen AW et al (1998) J Lab Clin Med 132: pp 363-368).
1. Neutralization of angiogenic factors - antivascular endothelial cell growth factor (VEGF) antibodies, dominant negative VEGF-receptors.
2. Inhibition of VEGF-receptors - anti-VEGFreceptor antibodies.
3. Desensitization of VEGF mediated intracellular signalling pathways - VEGF receptor tyrosine kinase inhibitor (e.g. SU5416, PTK787).
4. Inhibition of matrix metalloproteinases (marimastat, prinomastat).
5. Inhibition of endothelial cell adhesion (antiavb3- integrin antibody Vitaxin).
6. Inhibition of endothelial cell migration (interferon- alpha).
7. Inhibition of endothelial cell proliferation (TNP-470, angiostatin, endostatin, anginex).
While many anti-angiogenic therapies for treating cancer were highly active in animal models, clinical results so far tend to be rather disappointing. This may either be a result of the fact that the most promising anti-angiogenic compounds have not been tested in the clinic yet, or that the read-out systems available for measuring clinical efficacy of anti-tumor drugs are not suitable for measuring anti-angiogenic effects. One of the advantages of anti-angiogenic therapy is believed to be the lack of induction of resistance to the therapy (3). This is explained by the fact that endothelial cells are genetically stable cells that are considered not to mutate into drug resistant variants. Although this is a beneficial feature of the anti-angiogenic approach, it is expected that inhibitors of angiogenesis will be used in future in combination with other anti-cancer modalities such as chemotherapy, irradiation and/or immunotherapy.
References
1. Griffioen A, Molema G (2000) Angiogenesis: potentials for pharmacologic
intervention in the treatment of cancer, cardiovascular diseases and chronic inflammation. Pharmacol Rev 52: 237-268
2. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27- 31
3. Boehm T, Folkman J, Browder T, OReilly M S (1997) Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390: 404-407
For the main subject of this site, the holistic healing of cancer, refer to Healing Cancer Naturally & any of the menu points listed at the bottom and top of most
pages.
Disclaimer • Welcome • Why Alternatives ? • Alternative Cancer Therapy Guides
Johanna Budwig Diet & Protocol • Cancer Causes • Detoxification • Downloads
Emotions • Energetics • Geopathic Stress & Cancer • Gerson Therapy
Glossary • “Greatest Hits” • Hamer’s New Medicine • Healing Cancer
Medical History • Juicers & Juicing • Light Healing • Living Love
Lothar Hirneise • Healing & Your Mind • Nature Heals
Nutrition & Cancer • Ozone • Preventing Cancer
Self-Healing Links • Spirituality & Cancer
Supplements • Testimonials
Thoughts on Healing
Site Map
Write
us
•
You can contribute to this site’s maintenance by giving as little as $10.00.
Click here for details.
Dedicated to Joyful Healing
© 2004, 2005, 2006 & 2007
www.healingcancernaturally.com
All Rights Reserved
Copyright Notice
USE OF THIS SITE SIGNIFIES YOUR AGREEMENT TO THE DISCLAIMER.
Paradise Now
Ursula R. M. Schmid. P.O. Box 120244, 10592 Berlin, Germany,
Fax: +49 30 2639173 02053
